A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients with GEP-NET

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

332

Participants

Timeline

Start Date

October 22, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2027

Conditions
Gastro-enteropancreatic Neuroendocrine Tumor
Interventions
DRUG

CAM2029

CAM2029 (octreotide subcutaneous depot) 20 mg will be administered every 2 weeks as a subcutaneous injection

DRUG

Octreotide LAR

Octreotide LAR 30 mg will be administered every 4 weeks as an intramuscular injection

DRUG

Lanreotide ATG

Lanreotide ATG 120 mg will be administered every 4 weeks as a deep subcutaneous injection

Trial Locations (98)

10065

Memorial Sloan-Kettering Cancer Center, New York

10461

The Mount Sinai Hospital, The Bronx

10601

White Plains Hospital - Center for Cancer Care, White Plains

32224

Mayo Clinic Hospital - Florida, Jacksonville

33469

Anderson Family Cancer Institute, Jupiter

40536

University of Kentucky (UK) - Markey Cancer Center, Lexington

55905

Mayo Clinic Rochester, Rochester

70065

East Jefferson General Hospital, Metairie

75246

Texas Oncology - Dallas, Dallas

76201

Texas Oncology - Denton North, Denton

77030

The University of Texas - MD Anderson Cancer Center, Houston

78240

Texas Oncology - San Antonio Northeast, San Antonio

78503

Texas Oncology - McAllen, McAllen

78705

Texas Oncology - Austin, Austin

80218

Rocky Mountain Cancer Centers - Denver - Midtown, Denver

84112

Huntsman Cancer Institute, Salt Lake City

85054

Mayo Clinic Cancer Center (MCCC) - Phoenix, Phoenix

90404

UCLA Ahmanson Biological Imaging Center, Santa Monica

02215

Dana-Farber Cancer Institute, Boston

Unknown

The Queen Elizabeth Hospital (TQEH), Adelaide

GenesisCare - North Shore, Alexandria

Blacktown Hospital, Blacktown

Peter MacCallum Cancer Centre, Melbourne

Fiona Stanley Hospital, Murdoch

Cliniques Universitaires Saint-Luc, Brussels

Hôpital Erasme, Brussels

Antwerp University Hospital, Edegem

Algemeen Ziekenhuis Maria Middelares, Ghent

Universitair Ziekenhuis Leuven, Leuven

AZ Nikolaas, Sint-Niklaas

London Health Sciences Centre, London

Centre Hospitalier de l'Universite de Montreal - Notre-Dame Hospital, Montreal

Jewish General Hospital, Montreal

The Ottawa Hospital - General Campus, Ottawa

Niagara Health System - St. Catharines General Site, St. Catharines

Princess Margaret Cancer Centre, Toronto

Sunnybrook Health Sciences Centre, Toronto

BC Cancer Agency Vancouver Centre, Vancouver

CHU Hopitaux de Bordeaux - Hôpital Haut-Lévêque, Bordeaux

CHRU de Tours - Hopital Trousseau, Chambray-lès-Tours

Centre Hospitalier Universitaire Dijon Bourgogne - L'Hopital General, Dijon

Groupe Hospitalier de l'Institut Catholique de Lille - Hopital Saint Vincent de Paul, Lille

CHU de Lyon - Groupement Hospitalier Edouard Herriot, Lyon

CHU de Nantes - Hôtel-Dieu, Nantes

Centre Eugène Marquis, Rennes

Hôpitaux Universitaires de Strasbourg - Hôpital de Hautepierre, Strasbourg

Charite - UB - CVK - Medizinische Klinik, Berlin

Universitaetsklinikum Erlangen - Hautklinik, Erlangen

Universitätsklinikum Essen, Essen

Asklepios Klinik St. Georg, Hamburg

Universitätsklinikum Hamburg-Eppendorf (UKE), Hamburg

Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg, Heidelberg

Medizinischen Fakultät Mannheim der Universität Heidelberg, Mannheim

Universitätsklinikum Ulm, Ulm

SE ÁOK I. sz. Belgyógyászati Klinika, Budapest

Petz Aladár Megyei Oktató Kórház, Győr

Bács-Kiskun Megyei Kórház, Kecskemét

Szegedi Tudományegyetem; I.Belgyógyászati Klinika, Szeged

Rambam Medical Center, Haifa

Hadassah Medical Center (HMC) - Hadassah University Hospital (HUH) - Ein Kerem, Jerusalem

The Chaim Sheba Medical Center, Ramat Gan

Tel Aviv Sourasky Medical Center, Tel Aviv

Centro di Riferimento Oncologico (CRO), Aviano

Universita degli Studi di Bari - Aldo Moro, Bari

Azienda Ospedaliero - Universitaria di Bologna Policlinico S. Orsola - Malpighi, Bologna

ASST degli Spedali Civili di Brescia, Brescia

Universita degli Studi di Firenze - Azienda Ospedaliero - Universitaria Careggi - SC di Oncologia Medical, Florence

Universita Degli Studi di Genova - Center of Excellence for Biomedical Research (CEBR), Genova

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - IRST IRCCS, Meldola

Istituto Clinico Humanitas, Milan

Azienda Ospedaliero - Universitaria di Modena Policlinico, Modena

IRCCS - Istituto Nazionale dei Tumori di Napoli Fondazione G. Pascale - Oncologia Addominale, Napoli

Istituto Oncologico Veneto - IRCCS, Padua

Azienda Ospedaliera Sant'Andrea, Roma

Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Trento, Verona

Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis, Amsterdam

Rijnstate Ziekenhuis - Arnhem, Arnhem

Maastricht UMC+, Maastricht

Erasmus MC, Rotterdam

Institutul Clinic Fundeni, Bucharest

"Institutul Oncologic Prof. Dr. Ion Chiricuţă Cluj Napoca", Cluj-Napoca

Medisprof SRL, Cluj-Napoca

Sigmedical Services S.R.L., Suceava

Complexo Hospitalario Universitario A Coruña, A Coruña

Hospital Universitari Vall d'Hebron - Vall d'Hebron Institut d'Oncologia (VHIO), Barcelona

Institut Catala d'Oncologia Hospitalet, Barcelona

Hospital General Universitario de Elche, Elche

Hospital Universitari de Girona Doctor Josep Trueta, Girona

Facultad de Medicina - Hospital Universitario Fundacion Jimenez Diaz (UAM-FJD) (Clinica de la Concepcion), Madrid

Hospital Universitario Fundación Alcorcón, Madrid

Hospital Universitario La Paz (HULP), Madrid

Hospital Universitario Ramón y Cajal, Madrid

MD Anderson Cancer Center - Madrid, Madrid

Hospital Universitario Virgen de la Victoria, Málaga

Hospital General Universitario Morales Meseguer, Murcia

Hospital Universitario Central de Asturias, Oviedo

Parc Taulí Sabadell Hospital Universitari, Sabadell

Hospital Universitario Marques de Valdecilla (HUMV), Santander

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Camurus AB

INDUSTRY

NCT05050942 - A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients with GEP-NET | Biotech Hunter | Biotech Hunter